Colesevelam HCl improves glycemic control and reduces LDL cholesterol in patients with inadequately controlled type 2 diabetes on sulfonylurea-based therapy.

Diabetes Care · 2008 · PMC2494667 · PMID 18458145

Europe PMC DOI

hedged sentence

0.0630

closest p · 1.3× alpha

0.0630

boldest claim

The sentences

of marginal significanceP = 0.063so close (0.05 < p ≤ 0.1)

Inflammatory markers There was an LS median treatment difference of marginal significance in hsCRP by week 26 (LOCF; −0.40 ± 4.50 mg/l, P = 0.063).

also in 464 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.